Cardiovascular Risk Markers in Hemodialysis Patients

Cardiovascular events are the main cause of death in hemodialysis patients. Nevertheless, acute myocardial infarction may be misdiagnosed in uremic patients, because typical markers have a high rate of false positivity. A recent two-year prospective study showed that predialytic high serum concentrations of troponin T and CK-MB mass were associated with high mortality, cardiac mortality, myocardial infarction and unstable angina (MACEs). We studied 16 uremic patients (13 M; 3 W) on standard HD and 6 patients (4 M; 2 W) on on-line HDF, who had been taking folic acid for at least three months. Patients who suffered from acute or chronic cardiac ischemic disease were excluded. Anthropometric parameters, pre and post-dialytic pH, HCO3 and electrolytes did not differ between the two groups. Kt/V and URR % were lower in conventional HD vs on-line HDF (p<0.04; p<0.04). ORR % was strongly elevated in on-line HDF compared with HD (p<0.005). In conventional HD, ORR % was directly correlated with Kt/V and URR% (r = 0.49, p<0.04; r = 0.48, p<0.04, respectively). Even in on-line HDF ORR % was directly correlated with Kt/V and URR % (r = 0.79, p<0.04; r = 0.76, p<0.05, respectively). Troponin I and CK-MB mass were not significantly different in pre vs post-dialysis, both in standard HD and on-line HDF. Nevertheless, in standard HD postdialytic troponin I correlated with serum sodium concentration (r = 0.93, p < 0.000), potassium (r = 0.67, p < 0.004) and serum chlorine (r = 0.92, p < 0.92, p < 0.000). CK-MB mass showed a correlation with serum chlorine (r = 0.49, p < 0.05). Postdialytic CK-MB mass correlated with serum potassium in on-line HDF (r = 0.83, p < 0.03). Our data suggest that hemodialytic treatments, both standard HD and on-line HDF, do not modify serum troponin I and CK-MB mass. Consequently, we can use these parameters for the diagnostic approach in acute or chronic ischemic heart disease in hemodialysis patients.

[1]  P. Tuppin,et al.  Prognostic value of cardiac markers in ESRD: Chronic Hemodialysis and New Cardiac Markers Evaluation (CHANCE) study. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[2]  S. Lipsitz,et al.  Serum cardiac troponin and subclinical cardiac status in pediatric chronic renal failure. , 2003, Pediatrics.

[3]  Z. Massy Potential strategies to normalize the levels of homocysteine in chronic renal failure patients. , 2003, Kidney international. Supplement.

[4]  P. Stenvinkel,et al.  Hyperhomocysteinemia and its relationship to cardiovascular disease in ESRD: influence of hypoalbuminemia, malnutrition, inflammation, and diabetes mellitus. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[5]  Fred S Apple,et al.  Predictive Value of Cardiac Troponin I and T for Subsequent Death in End-Stage Renal Disease , 2002, Circulation.

[6]  P. Stenvinkel,et al.  Plasma sulfur amino acids in relation to cardiovascular disease, nutritional status, and diabetes mellitus in patients with chronic renal failure at start of dialysis therapy. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[7]  C. Enzinger,et al.  Hyperhomocysteinemia, pteridines and oxidative stress. , 2002, Current drug metabolism.

[8]  C. Zoccali,et al.  Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients. , 2002, Kidney international.

[9]  J. Selhub,et al.  Treatment of hyperhomocysteinemia in end-stage renal disease. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[10]  P O Collinson,et al.  Measurement of Cardiac Troponins , 2001, Annals of clinical biochemistry.

[11]  P. Tuppin,et al.  Factors associated with increased serum levels of cardiac troponins T and I in chronic haemodialysis patients: Chronic Haemodialysis And New Cardiac Markers Evaluation (CHANCE) study. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[12]  T. Meinertz,et al.  Implications of troponin testing in clinical medicine , 2001, Current controlled trials in cardiovascular medicine.

[13]  D. Wilcken,et al.  Homocysteine and cardiovascular disease: cause or effect? , 2000, The American journal of clinical nutrition.

[14]  S. Vollset,et al.  The controversy over homocysteine and cardiovascular risk. , 2000, The American journal of clinical nutrition.

[15]  Mohamed,et al.  Hyperhomocysteinemia, nutritional status, and cardiovascular disease in hemodialysis patients. , 2000, Kidney international.

[16]  A. Donker,et al.  Carotid artery stiffness in patients with end-stage renal disease: no effect of long-term homocysteine-lowering therapy. , 2000, Clinical Nephrology.

[17]  S. K. George,et al.  Current markers of myocardial ischemia and their validity in end-stage renal disease. , 1999, Current opinion in nephrology and hypertension.

[18]  S. Morgan,et al.  Cardiac troponin-I accurately predicts myocardial injury in renal failure. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[19]  R. Solaro,et al.  Troponin I, stunning, hypertrophy, and failure of the heart. , 1999, Circulation research.

[20]  A. Donker,et al.  The impact of an amino acid-based peritoneal dialysis fluid on plasma total homocysteine levels, lipid profile and body fat mass. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[21]  J. Hegbrant,et al.  Influence of haemodialysis on plasma total homocysteine concentration. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[22]  P. Ueland,et al.  Recent data are not in conflict with homocysteine as a cardiovascular risk factor. , 1998, Current opinion in lipidology.

[23]  A. Collins,et al.  Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. , 1998, The New England journal of medicine.

[24]  A. Donker,et al.  Folic Acid Treatment of Hyperhomocysteinemia in Peritoneal Dialysis Patients: No Change in Endothelial Function after Long Term Therapy , 1998, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[25]  G. Steinbach,et al.  Specificity of Cardiac Troponins I and T in Renal Disease , 1998, Clinical chemistry and laboratory medicine.

[26]  A. Bostom,et al.  Hyperhomocysteinemia in end-stage renal disease: prevalence, etiology, and potential relationship to arteriosclerotic outcomes. , 1997, Kidney international.

[27]  J. Witteman,et al.  Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. , 1997, JAMA.

[28]  F. T. Stevenson,et al.  Determinants of albumin concentration in hemodialysis patients. , 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[29]  P. Jungers,et al.  Hyperhomocysteinemia is associated with atherosclerotic occlusive arterial accidents in predialysis chronic renal failure patients. , 1997, Mineral and electrolyte metabolism.

[30]  P. Ueland Plasma homocysteine as a risk factor for cardiovascular disease and as an indicator of vitamin deficiencies , 1996 .

[31]  G. Omenn,et al.  A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. , 1995, JAMA.

[32]  E. Livant,et al.  Plasma folate conjugase activities and folate concentrations in patients receiving hemodialysis , 1994 .

[33]  B. Pau,et al.  Cardiac-specific immunoenzymometric assay of troponin I in the early phase of acute myocardial infarction. , 1993, Clinical chemistry.

[34]  S. Perry The regulation of contractile activity in muscle. , 1979, Biochemical Society transactions.

[35]  J. Wilkinson,et al.  Comparison of amino acid sequence of troponin I from different striated muscles , 1978, Nature.

[36]  I. Goldman,et al.  Inhibition of the membrane transport of folates by anions retained in uremia. , 1975, The Journal of laboratory and clinical medicine.